3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Prostatic Neoplasms
12
Neoplasms
11
Neuroendocrine Tumors
9
Breast Neoplasms
9
Lung Neoplasms
6
Neoplasm Metastasis
4
Multiple Myeloma
4
Disease
4
Uterine Cervical Neoplasms
3
Lymphoma, Non-Hodgkin
3
Lymphoma
3
Head and Neck Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Urinary Bladder Neoplasms
2
Stomach Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Rectal Neoplasms
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Pancreatic Neoplasms
2
Neoplastic Cells, Circulating
2
Mouth Neoplasms
2
Lymphoma, Follicular
2
Liver Neoplasms
2
Leukemia
2
Hypoxia
2
Hodgkin Disease
2
Glioma
2
Esophageal Neoplasms
2
Carcinoma, Neuroendocrine
2
Brain Neoplasms
2
Interventions
Dexamethasone
110
Cyclophosphamide
99
Melphalan
91
Bortezomib
68
Peripheral Blood Stem Cell Transplantation
63
Lenalidomide
57
fludarabine phosphate
55
Busulfan
53
Filgrastim
50
Antilymphocyte Serum
38
Tacrolimus
37
Thalidomide
36
Radiotherapy
36
Mycophenolic Acid
32
fludarabine
28
Cyclosporine
26
Methotrexate
25
Etoposide
22
Calcium Dobesilate
22
Prednisone
21
Whole-Body Irradiation
20
Methylprednisolone
20
sargramostim
19
pomalidomide
19
Granulocyte Colony-Stimulating Factor
18
carfilzomib
16
daratumumab
15
Cord Blood Stem Cell Transplantation
14
Carmustine
14
Rituximab
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Neoplasms, Plasma Cell
×
Positron Emission Tomography Computed Tomography
×
Clear all
NCT03314636
2025-08-08
CONPET
Oslo University Hospital
Phase 2
Active not recruiting
53 enrolled